Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03478787 · ClinicalTrials.gov registry record · Phase 3
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 327
- Enrollment target
- 20
- Study locations
NCT03478787 is a Phase 3 study of Psoriasis that has completed, run by AbbVie. The registered enrollment target is 327 participants, below the 486-participant average among 125 other Psoriasis trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT03478787, a Phase 3 study of Psoriasis, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 327 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Conditions Studied
Interventions
- DRUG risankizumab
- DRUG secukinumab
Study Locations (20)
California
- Bakersfield Derma & Skin Cance /ID# 202115 - Bakersfield
- Center for Dermatology Clin Res /ID# 202116 - Fremont
- Dermatology Res. Assoc., CA /ID# 202170 - Los Angeles
- UC Davis Health /ID# 202263 - Sacramento
- Medderm Associates /ID# 202162 - San Diego
Florida
- Tory P Sullivan, MD PA /ID# 202177 - North Miami Beach
- Renstar Medical Research /ID# 202113 - Ocala
- Progressive Medical Research /ID# 202183 - Port Orange
- Integrated Clinical Research LLC /ID# 202152 - West Palm Beach
Arizona
- Advanced Research Associates - Glendale /ID# 204335 - Glendale
- Alliance Dermatology and MOHs /ID# 204336 - Phoenix
Massachusetts
- ORA, Inc. /ID# 204342 - Andover
- Beth Israel Deaconess Medical Center /ID# 204340 - Boston
Connecticut
- UConn Health Main /ID# 201745 - Farmington
Kentucky
- Dermatology Specialists Resear /ID# 202145 - Louisville
Maryland
- Dermatology and Skin Cancer Specialists, LLC /ID# 203938 - Rockville
Minnesota
- Minnesota Clinical Study Center /ID# 202369 - New Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2018-05-08 |
| Est. Completion | 2020-07-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03478787
The ClinicalTrials.gov registry entry for NCT03478787 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 486-participant average among 125 other Psoriasis trials with a reported enrollment target (33% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which risankizumab is the first listed.
NCT03478787 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03478787 about?
NCT03478787 is a clinical study titled "Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis". The main objective of this study is to evaluate the efficacy and safety of risankizumab compared with secukinumab for the treatment of adult subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy.
What is the current status of trial NCT03478787?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 327 participants. The study started on 2018-05-08. Estimated completion is 2020-07-08.
What conditions does trial NCT03478787 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT03478787?
The interventions under investigation include: risankizumab (DRUG), secukinumab (DRUG).
Who is sponsoring clinical trial NCT03478787?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03478787 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.